Imatinib does not impair specific antitumor T-cell immunity in patients with chronic myeloid leukemia.
Bocchia
M
M
Abruzzese
E
E
Forconi
F
F
Ippoliti
M
M
Trawinska
M M
MM
Pirrotta
M T
MT
Raspadori
D
D
Tozzi
M
M
Gozzetti
A
A
Lauria
F
F
D000293:Adolescent; D000328:Adult; D001549:Benzamides; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D002648:Child; D004354:Drug Screening Assays, Antitumor; D006801:Humans; D000068877:Imatinib Mesylate; D007111:Immunity, Cellular / Q000187:drug effects*; D007114:Immunization; D016898:Interferon-alpha / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology*
D001549:Benzamides; D016898:Interferon-alpha; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate